A trio of experts talked about Lexeo Therapeutics’ LX1001 gene therapy trial that demonstrated promising safety and biomarker effects in patients with early-stage Alzheimer disease. [WATCH TIME: 5 minutes]
R. Nolan Townsend
Advertisement
Chief executive officer at Lexeo.
Articles by R. Nolan Townsend
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
FDA Clears Roche’s Elecsys pTau181 Test for Ruling Out Alzheimer-Related related Amyloid Pathology
2
Inside the Phase 3 MASCOT Trial: Lundbeck’s Push for the First Disease-Modifying MSA Therapy
3
Phase 2 OPAL Study to Test Muscle-Targeting Therapy Apitegromab in Infants With SMA
4
Decision-Making in De-Escalating Therapy for Multiple Sclerosis
5
